Subscribe
dentist_istock-532326710_pyotr021
pyotr021 / iStockphoto.com
22 February 2018Big Pharma

J&J to boost medical device division with acquisition

Johnson & Johnson (J&J) has revealed plans to strengthen its medical device capabilities with the acquisition of French medical technology company Orthotaxy.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
J&J plans to sell LifeScan for $2.1bn
21 March 2018   Johnson & Johnson has revealed plans to sell LifeScan, its blood glucose monitoring unit, for $2.1 billion.
Americas
J&J to buy surgical robotics company for $3.4bn
18 February 2019   Johnson & Johnson has announced plans to strengthen its robotics programme with the addition of Silicon Valley-based Auris Health to its business.


Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024

Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024

More on this story

Americas
J&J plans to sell LifeScan for $2.1bn
21 March 2018   Johnson & Johnson has revealed plans to sell LifeScan, its blood glucose monitoring unit, for $2.1 billion.
Americas
J&J to buy surgical robotics company for $3.4bn
18 February 2019   Johnson & Johnson has announced plans to strengthen its robotics programme with the addition of Silicon Valley-based Auris Health to its business.

More on this story

Americas
J&J plans to sell LifeScan for $2.1bn
21 March 2018   Johnson & Johnson has revealed plans to sell LifeScan, its blood glucose monitoring unit, for $2.1 billion.
Americas
J&J to buy surgical robotics company for $3.4bn
18 February 2019   Johnson & Johnson has announced plans to strengthen its robotics programme with the addition of Silicon Valley-based Auris Health to its business.

More features

Gilead awarded $30m over counterfeit HIV drug scheme
EPO invalidates human milk patent after Nestle opposition
Bayer gains exclusive licence for heart drug in Japan
EPO delivers key Novo Nordisk, GSK and Inhibrx rulings
McGuireWoods expands team with ex-Novo Nordisk GC
Paul, Weiss swoops for senior duo from Weil, Gotshal
UPC bans Meril Life Sciences from selling infringing heart valve
SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic